Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuina Ueda-Akagi

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Internal Medicine (Tokyo, Japan)|October 29, 2025
Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like SyndromeSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Leukemia & Lymphoma|December 25, 2025
Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatmentSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Internal Medicine (Tokyo, Japan)|October 29, 2025
Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like SyndromeSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Leukemia & Lymphoma|December 25, 2025
Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatmentSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Pageof 1